JAK3 and acute lymphoblastic leukemia: Studies have identified mutated or overexpressed IL-7R, JAK1, or JAK3 as oncoproteins in patients with T-ALL and validated them as oncogenic drivers in mouse models (8, 9, 12, 14, 63).